As some pharmaceutical companies have shown, covid-19 times are tough. But Dr Reddy’s Laboratories Ltd’s results exhibit that pharma companies can still pull through quite nicely.
Steady performance in the fourth quarter in all its divisions drove its shares up 5.7% on Wednesday. However, future gains will hinge heavily on how the company can further drive margin expansion While the results were just a step ahead of analysts’ expectations, the fact that the company is focusing on sturdy improvements in operations is being seen as key to growth.
In fact, overall revenues in Q4 were up 1.1% quarter-on-quarter. Growth in some key markets such as the US is encouraging. Notably, its North American Q4 revenues rose about 13% q-o-q following